br since as the linear energy transfer LET

since, as the linear Rapamycin transfer (LET) increases, radiation produces vantages over 177Lu-iPSMA and 223RaCl2 in the treatment of bone
E. Azorín-Vega et al.
metastases in patients with advanced prostate cancer. Experimental models are necessary to evaluate the relative biological effectiveness value of 225Ac-iPSMA as well as its stability in bone tissue.
Conflicts of interest
The authors declare no competing financial interest.
Acknowledgment
This study was performed as part of the activities of the “Laboratorio Nacional de Investigación y Desarrollo de Radiofármacos-CONACyT”. Grant 293334.
Appendix A. Supplementary data
References
metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 19 (6), 825–833.
International Comission on Radiation Units and Measurements, 1989. Tissue Substitutes in Radiation Dosimetry and Measurement, vol. 23 1. https://doi.org/10.1093/jicru/ os23.1.Report44. International Commission on Radiation Protection, 1995. Basic anatomical & physiolo-gical data for use in radiological protection - the skeleton. ICRP publication 70. Ann. ICRP 25 (2). Kratochwil, C., Bruchertseifer, F., Rathke, H., Hohenfellner, M., Giesel, F.L., Haberkorn, U., Morgenstern, A., 2018. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy re-garding duration of tumor control. J. Nucl. Med. 59 (5), 795–802.
Luna-Gutierrez, M., Hernandez-Jimenez, T., Serrano-Espinoza, L., Pena-Flores, A., Soto-Abundiz, A., 2017. Freeze-dried multi-dose kits for the fast preparation of 177Lu-Tyr3-octreotide and 177Lu-PSMA(inhibitor) under GMP conditions. J. Radioanal. Nucl.
Wüstemann, T., Bauder-Wüst, U., Schäfer, M., Eder, M., Benesova, M., Leotta, K., 2016. Design of internalizing PSMA-specific Glu-ureido-based radiotherapeuticals.
Contents lists available at ScienceDirect
Lung Cancer
journal homepage: www.elsevier.com/locate/lungcan
Association between antibiotic-immunotherapy exposure ratio and outcome T in metastatic non small cell lung cancer
Giulia Gallia, Tiziana Triulzib, Claudia Protoa, Diego Signorellia, Martina Imbimboa, Marta Poggia, Giovanni Fucàa, Monica Ganzinellia, Milena Vitalia, Dario Palmierid, Anna Tessarid,
Filippo de Brauda,c, Marina Chiara Garassinoa, Mario Paolo Colombob, Giuseppe Lo Russoa,
a Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian 1, 20133, Milan, Italy
b Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, via Amadeo 42, 20133, Milan, Italy
c Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, via Festa del Perdono 7, 20122, Milan, Italy
d Department of Cancer Biology and Genetics, The Ohio State University, 460w 12th avenue, 43210, Columbus, OH, USA
Keywords:
Antibiotic
Immunotherapy
Microbiota
Non small cell lung cancer 
Objectives: Immunotherapy (IO) is effective in metastatic Non Small Cell Lung Cancer (NSCLC). Gut microbiota has an impact on immunity and its imbalance due to antibiotics may impair the efficacy of IO. We investigated this topic in a case series of NSCLC patients treated with IO.
Materials and Methods: Data about all metastatic NSCLC patients treated with IO between 04/2013 and 01/2018 were collected. Patients were stratified according to antibiotic use during the Early IO Period (EIOP), and ac-cording to the Antibiotic-Immunotherapy Exposure Ratio (AIER) defined as “days of antibiotic/days of IO” during the Whole IO Period (WIOP). Survival was estimated using the Kaplan-Meier method. Log-rank test was used to compare the curves. Multivariate analyses were performed with the Cox model.